TAT-RasGAP 317-326 kills cells by targeting inner-leaflet–enriched phospholipids
Résumé
TAT-RasGAP 317–326 is a cell-penetrating peptide-based construct with anticancer and antimicrobial activities. This peptide kills a subset of cancer cells in a manner that does not involve known programmed cell death pathways. Here we have elucidated the mode of action allowing TAT-RasGAP 317–326 to kill cells. This peptide binds and disrupts artificial membranes containing lipids typically enriched in the inner leaflet of the plasma membrane, such as phosphatidylinositol-bisphosphate (PIP 2 ) and phosphatidylserine (PS). Decreasing the amounts of PIP 2 in cells renders them more resistant to TAT-RasGAP 317–326 , while reducing the ability of cells to repair their plasma membrane makes them more sensitive to the peptide. The W317A TAT-RasGAP 317–326 point mutant, known to have impaired killing activities, has reduced abilities to bind and permeabilize PIP 2 - and PS-containing membranes and to translocate through biomembranes, presumably because of a higher propensity to adopt an α-helical state. This work shows that TAT-RasGAP 317–326 kills cells via a form of necrosis that relies on the physical disruption of the plasma membrane once the peptide targets specific phospholipids found on the cytosolic side of the plasma membrane.
Domaines
Biophysique
Origine : Fichiers produits par l'(les) auteur(s)